- Home
- NVX vs PLX Comparison
NVX vs PLX Comparison
Compare NVX & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVX | PLX |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 245.7M | 204.9M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | NVX | PLX |
|---|---|---|
| Price | $1.12 | $1.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.6M | 570.7K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $5,931,433.00 | ★ $61,840,000.00 |
| Revenue This Year | $165.90 | $14.53 |
| Revenue Next Year | $1,344.85 | $75.77 |
| P/E Ratio | ★ N/A | $24.25 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $0.81 | $1.32 |
| 52 Week High | $3.86 | $3.10 |
Technical Indicators
Market Signals| Indicator | NVX | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.12 | 35.14 |
| Support Level | $1.05 | $1.71 |
| Resistance Level | $1.20 | $1.86 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 55.36 | 16.67 |
Price Performance
Historical ComparisonAbout NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.